Multiple myeloma (MM) is a clonal plasma cell disorder defined by bone marrow infiltration and osteolytic bone lesions and is the second most common hematologic malignancy after non-Hodgkin lymphoma.
antibodies, next generation proteasome inhibitors, epigenetic modulation with histone deacetylase inhibitors, and targeting the tumor microenvironment. In this article, the diagnosis, staging, and prognostic stratification of newly diagnosed MM will be reviewed. Clinical data pertaining to the emerging targeted agents will be discussed, and a suggested framework for integration of these new therapeutic options will be provided. compared to patients diagnosed prior to the era of novel agents [3] . In this review, diagnosis and risk stratification, recommendations for initial and subsequent therapy, and a discussion regarding emerging therapies for MM will be provided. This review is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
DIAGNOSIS
A monoclonal protein may be discovered in the serum or urine following diagnostic testing for a variety of conditions including the evaluation of anemia, renal impairment, hypercalcemia, musculoskeletal pain, or neurologic conditions. A diagnostic panel of serum protein electrophoresis (SPEP), serum immunofixation (IFE), and the serum FLC assay should be obtained when MM is suspected. The serum FLC assay quantifies kappa and lambda light chains circulating unbound from the heavy chain and detects a clonal process by the alteration of the kappa/lambda ratio. In a study involving 1877 samples, sensitivity for detection of monoclonal proteins in MM was 87 .6% for SPEP, 94.4% for serum IFE, and 98.6% for serum FLC, with a combined 100% diagnostic sensitivity [5] . If a patient is diagnosed with a plasma cell disorder by initial screening, then a 24- median OS 29 months) [16] . The ISS has also been validated in patients treated with novel agents, and 5-year survival in stages I, II, and III patients was significantly different between groups at 66 %, 45 %, and 18 %, respectively (P\0.001) [17] .
The development of interphase fluorescent in situ hybridization (FISH) to detect recurrent cytogenetic abnormalities has been a critical factor in identifying variability intrinsic to the plasma cell clone [18] . Table 3 .
Next Generation Proteasome Inhibitors
The proteasome is a key structure within the nucleus and cytoplasm of eukaryotic cells that degrades ubiquinated proteins and is involved in cell homeostasis [65] . The ubiquitin-proteasome pathway is a rational 
Monoclonal Antibodies
The next major breakthrough in the therapy of MM is likely to be the effective incorporation of monoclonal antibodies. Multiple novel targets have been identified, and the three agents in phase III testing include elotuzumab (antiCS-1/ SLAM7) and the anti-CD38 antibodies daratumumab and SAR650984. Elotuzumab was tested in combination with bortezomib in a phase I dose-escalation study and achieved an ORR of 48% and median PFS of 9.5 months with no dose-limiting toxicities [83] . Elotuzumab in combination with lenalidomide and dexamethasone demonstrated a significant increase in activity (ORR 82%, CVGPR 29%), suspected to be due to a synergistic induction of ADCC-mediated apoptosis [84] . In the recent phase III study of Rd with or without elotuzumab (ELOQUENT-2), median PFS was 19.4 vs. 14.9 months in the control group (HR 0.70; P\0.001), and ORR improved to 79% in the elotuzumab arm versus 66% with Rd (P\0.001) [85] .
Daratumumab demonstrated single-agent dose-dependent efficacy in a phase I dose-escalation study with the most common adverse event of mild infusion-related events, especially during the initial treatment [86] . ORR was 46% in patients treated at the 16 mg/kg dose level, and no dose-related increase in adverse effects was observed. In preclinical studies, lenalidomide enhances the anti-MM activity of daratumumab [87] . infusion-related reactions in 39% (predominantly cycle 1). The dose of 10 mg/kg every 2 weeks was selected for an expansion cohort [89] .
Siltuximab is a chimeric monoclonal antibody against IL-6 and has been evaluated as an adjunct to novel agents in the treatment of MM. In a phase II randomized study of VMP or VMP plus siltuximab followed by siltuximab maintenance in newly diagnosed MM patients, median PFS and 1-year OS were identical in both arms (17 months and 88%, respectively), while more hematologic events and infections occurred in the siltuximab group [90] . In the relapsed setting, the addition of siltuximab to bortezomib did not significantly improve the response rate or PFS 
